Compare JPMorgan Ultra Short Income ETF (JPST) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Ultra Short Income ETF vs Recursion Pharmaceuticals Inc — how do they compare? JPMorgan Ultra Short Income ETF trades at $50.28 (market cap $42.37B), while Recursion Pharmaceuticals Inc trades at $4.02 (market cap $2.14B). The key difference: JPMorgan Ultra Short Income ETF is far larger — about 19.8× Recursion Pharmaceuticals Inc's market cap, and Recursion Pharmaceuticals Inc is trading nearer its 52-week high, JPMorgan Ultra Short Income ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold JPMorgan Ultra Short Income ETF for 46 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| JPST | RXRX | |
|---|---|---|
Market Cap | $42.37B | $2.14B |
Volume | 7,889,185 | 30,789,535 |
Sector | Fixed Income | Health |
52-Week High | $50.78 | $6.79 |
52-Week Low | $50.22 | $2.84 |
Typical Hold Time | 46 Days | 22 Days |
Enterprise Value | — | $1.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JPST trades at $50.27, up 0.04% with a bearish technical signal from moving averages. The ETF shows neutral oscillators like RSI near 35, while recent news highlights institutional selling and mixed sentiment on its yield competitiveness. Dividend payments of $0.17 are scheduled through October 2026, but key financial ratios are unavailable for fundamental assessment.
Outlook remains cautious due to technical weakness and underperformance concerns cited by analysts. Risks include interest rate sensitivity and expense ratios, but demand for ultra-short income ETFs amid market volatility offers stability. Investors should weigh yield against peer comparisons and fee structures.
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About JPMorgan Ultra Short Income ETF
JPST is an actively managed ETF that invests in short-term, investment-grade fixed income securities. It aims to provide current income and capital preservation while maintaining high liquidity.
Read more on JPST →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
